Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.62 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | HEXA | P06865 | 1/20 | 0.43 |
| ▸ | HEXB | P07686 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259992 | 0.83 | HEXA (0.56) | DHFRUSP7HEXAHEXB | |
| SCHEMBL29913449 | 0.77 | DHFR (0.66) | DHFRIKBKEUSP7HEXAHEXB | |
| SCHEMBL11881285 | 0.77 | DHFR (1.00) | DHFRHEXAHEXB | |
| SCHEMBL29913145 | 0.77 | DHFR (1.00) | DHFRHEXAHEXB | |
| SCHEMBL29913304 | 0.71 | DHFR (0.66) | DHFRIKBKEUSP7HEXAHEXB | |
| SCHEMBL7433870 | 0.70 | BACE1 (0.59) | DHFRBACE1MAP4K4 | |
| SCHEMBL4808328 | 0.69 | DHFR (0.52) | DHFRIKBKEBACE1DPP4MAP4K4 | |
| SCHEMBL10344628 | 0.69 | BACE1 (0.53) | DHFRBACE1DPP4MAP4K4 | |
| SCHEMBL28463380 | 0.68 | DHFR (0.39) | DHFRHEXAHEXBBACE1MAP4K4 | |
| SCHEMBL21223518 | 0.68 | DHFR (0.61) | DHFRIKBKEBACE1PTPN11DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | KEAP1, GSTK1, NFE2L2 | DHFR 1701/4885IKBKE 243/4885USP7 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.